Efficacy and safety of latanoprost versus travoprost for primary open-angle glaucoma and ocular hypertension: A meta-analysis

Chinese Journal of Evidence-Based Medicine

Volumn 11, Issue 8, 2011, Pages 965-970

  Qian, Zhi Gang ^a   Ke, Min ^b   Huang, Gang ^a   Zou, Juan ^a  

^a Department of Ophthalmology   (China)

^b ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

Efficacy; Latanoprost; Met analysis; Ocular hypertension; Primary open angle glaucoma; Safety; Systematic review; Travoprost

Indexed keywords

LATANOPROST; TRAVOPROST;

DEPIGMENTATION; DRUG EFFICACY; DRUG SAFETY; EYE PAIN; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; IRIS DISEASE; META ANALYSIS; OPEN ANGLE GLAUCOMA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT OUTCOME;

EID: 80052161817     PISSN: 16722531     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (17)

1. Higginbotham EJ, Schuman JS, Goldberg I, et al. One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch Ophthalmol, 2002, 120(10): 1286-1293.
2. Hedman K, Alm A. A pooled-data analysis of three randomized, double-masked, sixmonth clinical studies comparing the intraocular pressure reducing effect of latanoprost and timolol. Eur J Ophthalmol, 2000, 10(2): 95-104.
3. Netland PA, Landry T, Sullivan EK, et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol, 2001, 132(4): 472-484.
4. van der Valk R, Webers CA, Schouten JS, et al. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a met-analysis of randomized clinical trials. Ophthalmology, 2005, 112(7): 1177-1185.
5. McKee HD, Gupta MS, Ahad MA, et al. First-choice treatment preferences for primary open-angle glaucoma in the United Kingdom. Eye, 2005, 19(8): 923-924.
6. Parrish RK, Palmberg P, Sheu WP, et al. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol, 2003, 135(5): 688-703.
7. Chinese Sources
8. Dubiner HB, Sircy MD, Landry T, et al. Comparison of the diurnal ocular hypotensive efficacy of travoprost and latanoprost over a 44-hour period in patients with elevated intraocular pressure. Clin Ther, 2004, 26(1): 84-91.
9. Orzalesi N, Rossetti L, Bottoli A, et al. Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Ophthalmology, 2006, 113(2): 239-246.
10. Parmaksiz S, Yüksel N, Karabas VL, et al. A comparison of travoprost, latanoprost, and the fixed combination of dorzolamide and timolol in patients with pseudoexfoliation glaucoma. Eur J Ophthalmol, 2006, 16(1): 73-80.
11. Garcia-Feijoo J, Martinez-de-la-Casa JM, Castillo A, et al. Circadian IOP-lowering efficacy of travoprost 0.004% ophthalmic solution compared to latanoprost 0.005%. Curr Med Res Opin, 2006, 22(9): 1689-1697.
12. Chen MJ, Chen YC, Chou CK, et al. Comparison of the effects of latanoprost and travoprost on intraocular pressure in chronic angle closure glaucoma. J Ocul Pharmacol Ther, 2006, 22(6): 449-454.
13. Hepsen IF, Ozkaya E. 24-h IOP control with latanoprost, travoprost, and bimatoprost in subjects with exfoliation syndrome and ocular hypertension. Eye, 2007, 21(4): 453-458.
14. Koz OG, Ozsoy A, Yarangumeli A, et al. Comparison of the effects of travoprost, latanoprost and bimatoprost on ocular circulation: a 6-month clinical trial. Acta Ophthalmol Scand, 2007, 85(8): 838-843.
15. Maul E, Carrasco FG, Costa VP, et al. A 6-week, multicenter, randomized, double-masked, parallel-group study comparing travoprost 0.004% to latanoprost 0.005% followed by 6-week, open-label treatment with travoprost 0.004%. Clin Ther, 2007, 29(9): 1915-1923.
16. Chiselita D, Antohi I, Medvichi R, et al. Comparative analysis of the efficacy and safety of latanoprost, travoprost and the fixed combination timolol-dorzolamide; a prospective, randomized, masked, cross-over design study. Oftalmologia, 2005, 49(3): 39-45.
17. Whitson JT, Trattler WB, Matossian C, et al. Ocular surface tolerability of prostaglandin analogs in patients with glaucoma or ocular hypertension. J Ocul Pharmacol Ther, 2010, 26(3): 287-292.